$250,000 Donation Supports UC Digestive Disease Studies
The University of Cincinnati College of Medicine has received a $250,000 endowment to further education and research in digestive diseases.
The funding, donated by Gwendolyn Shapiro in memory of her late husband, Nathan Shapiro, MD, will establish the Dr. Nathan Shapiro Award Fund in the UC division of digestive diseases. It will provide an annual financial award that will allow a gastroenterology fellow to learn from outstanding researchers in the field and explore new areas of investigation.
The Shapiro Fund is especially important to the College of Medicine and the division of digestive diseases, said David Stern, MD, College of Medicine dean, since it will reward outstanding fellows and help them become leaders in academic gastroenterology. We are grateful for Mrs. Shapiros generosity and honor her vision of continuing her husbands work of advancing digestive disease science.
A 1937 graduate of UC College of Medicine, Dr. Shapiro was a physician with Cincinnati Digestive Diseases Inc. and had served as senior attending physician at Jewish Hospital and as a clinical professor of medicine at UC until his retirement in 1997. He died in 2004.
Related Stories
UC experts say proper produce washing is key defense against Cyclospora
July 17, 2026
Hamilton County Public Health reports confirmed cases of cyclosporiasis, as concerns persist. Cyclospora is a parasite that can cause a stomach illness lasting days — sometimes even weeks. University of Cincinnati medical experts say it is usually linked to contaminated water or food, often fresh produce.
UC students organize free health clinic in community
July 15, 2026
The University of Cincinnati student chapter of Remote Area Medical held its annual free health clinic July 11-12 at St. Xavier High School. Medical, dental and vision care was offered to adults and children, with no income requirements or insurance needed.
University of Cincinnati advances FLASH radiation therapy with new clinical trial
July 15, 2026
UC Cancer Center researchers led the FAST-02 trial, showing ultra-high-dose-rate FLASH proton therapy near the heart and lungs safely reduced pain from thoracic bone metastases.